CapsoVision, Inc: A Plain-English Investor Guide

I wrote this guide to help you understand CapsoVision’s performance. My goal is to explain their latest filings in plain English so you can decide if this company fits your goals.

1. What does this company do?

CapsoVision makes medical technology for non-invasive imaging. Their main product, the "CapsoCam Plus," is a 360-degree capsule endoscope. Patients swallow it to visualize the small bowel. Unlike traditional endoscopy, this procedure requires no sedation or invasive tools. The company makes money by selling these single-use capsules and the "CapsoView" software that doctors use to analyze the images.

2. Financial health: The "Going Concern" warning

The company is in a fragile financial position. Their latest report includes a "going concern" warning. As of December 31, 2025, they held $18.4 million in cash but reported a $32.7 million annual loss. Auditors doubt the company can stay in business because they burn $2.5 million per month. This leaves them with less than eight months of cash. Their 42% profit margin on sales cannot cover their high research and administrative costs. They expect to lose money through at least 2027.

3. Major wins and hurdles

• The Big Win: They went public in July 2025, raising $65 million on the Nasdaq (ticker: CV). This cash helped them pay off $12 million in loans and fund operations.
• The Hurdle: They rely on one product. About 94% of their $22 million in annual revenue comes from the CapsoCam Plus. They are developing a "CapsoCam Colon" for the larger colorectal market. They have spent $15 million on trials for this, but they do not expect sales until mid-2027, pending FDA approval.

4. Future outlook: The long road ahead

The company is focusing on three main areas:

• New Markets: They want to expand into pediatric care and integrate with telehealth. They hope to grow their total market size by 15% by 2028.
• New Tech: They are building "CapsoCloud" AI software. This should help doctors review images 40% faster by automatically flagging potential issues.
• The Colon Product: This is their most important project. They are testing it on 800 patients. Success depends on proving it works as well as a traditional colonoscopy to win FDA approval.

5. Key risks for investors

• Running out of cash: With a $32.7 million annual loss, the company will likely need to raise $40–$50 million by late 2026. This will mean issuing more shares, which reduces your ownership percentage.
• Supply Chain: They rely on two manufacturers in Taiwan and Japan for all components. Any regional conflict or disruption could stop production, as they only keep 60 days of inventory.
• Clinical Success: The stock price depends on the CapsoCam Colon. If trials fail or the FDA demands more studies, their growth plan could collapse, likely hurting the stock price.

6. The Bottom Line

CapsoVision is a high-risk, high-reward startup. They have patented technology but are burning cash quickly and rely on one product. This is not a stable, profitable company yet. If you want a speculative medical tech play, watch their cash burn and FDA updates closely. Expect volatility until they show a path to profit or find a partner.

Investor Checklist: Before buying, ask yourself if you are comfortable with the high probability of share dilution and the binary nature of their upcoming FDA clinical results. If you prefer stability, this may not be the right fit for your portfolio.